Globus Medical (GMED) Surpasses Q4 Earnings and Revenue Estimates

Core Viewpoint - Globus Medical reported strong quarterly earnings of $1.28 per share, exceeding the Zacks Consensus Estimate of $1.06 per share, and showing significant growth from $0.84 per share a year ago, indicating a positive earnings surprise of +20.76% [1] Financial Performance - The company achieved revenues of $826.42 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.90% and reflecting a year-over-year increase from $657.29 million [2] - Over the last four quarters, Globus Medical has exceeded consensus EPS estimates three times and has also topped revenue estimates three times [2] Stock Performance - Since the beginning of the year, Globus Medical shares have increased by approximately 7%, contrasting with a slight decline of 0.1% in the S&P 500 [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations for it to outperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.85 on projected revenues of $734.46 million, while the estimate for the current fiscal year stands at $3.89 on revenues of $3.15 billion [7] - The trend of estimate revisions for Globus Medical has been favorable leading up to the earnings release, which may influence future stock movements [5][6] Industry Context - The Medical - Instruments industry, to which Globus Medical belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]